Scinai Immunotherapeutics annual r&d spending
2017
2020
2021
2022
2023
2024
2025
Scinai Immunotherapeutics R&D Spending Growth & History (SCNI)
Scinai Immunotherapeutics's r&d spending was $2.4M for fiscal 2025.
View full Scinai Immunotherapeutics company overviewScinai Immunotherapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.4M | −$3.2M | −57.18% |
| 2024 | 2024-12-31 | $5.5M | $322,000 | +6.18% |
| 2023 | 2023-12-31 | $5.2M | −$555,000 | −9.63% |
| 2022 | 2022-12-31 | $5.8M | $2.4M | +73.38% |
| 2021 | 2021-12-31 | $3.3M | −$12.7M | −79.23% |
| 2020 | 2020-12-31 | $16.0M | — | — |
| 2017 | 2017-12-31 | $5.4M | — | — |
Scinai Immunotherapeutics quarterly r&d spending
Q1.22
Q2.22
Q1.23
Q2.23
Q4.24
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $211,000 | $269,000 | — |
| Q1 2026 | 2026-03-31 | $628,000 | −$667,000 | −51.51% |
| Q2 2025 | 2025-06-30 | −$58,000 | — | — |
| Q1 2025 | 2025-03-31 | $1.3M | — | — |
| Q4 2024 | 2024-12-31 | $1.3M | — | — |
| Q2 2023 | 2023-06-30 | $1.5M | −$520,000 | −26.34% |
| Q1 2023 | 2023-03-31 | $2.0M | $832,000 | +71.54% |
| Q2 2022 | 2022-06-30 | $2.0M | — | — |
| Q1 2022 | 2022-03-31 | $1.2M | — | — |
Scinai Immunotherapeutics r&d spending trends
Over the last five fiscal years, Scinai Immunotherapeutics's r&d spending decreased from $16.0M to $2.4M, a change of −$13.6M. The latest reported quarter, Q2 2026, shows $211,000.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Scinai Immunotherapeutics source filings ↗